Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.68 |
| ▸ | ECE1 | P42892 | 8/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MPO | P05164 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603940 | 1.00 | ACE (0.68) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL14941216 | 1.00 | ACE (0.68) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL29603737 | 0.95 | ACE (0.62) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL29603579 | 0.95 | ACE (0.62) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL29975563 | 0.92 | ACE (0.64) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL9852039 | 0.92 | ACE (0.67) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL9852029 | 0.92 | ACE (0.67) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL5583839 | 0.92 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL3359705 | 0.92 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL11855463 | 0.92 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702044-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2026-03-04 | — | — | EP | claimed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245288-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| WO-2025123055-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025123059-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025123056-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| CN-118731374-B | Method for predicting deposition net energy of growing pigs | 中国农业大学 | 2024-11-22 | — | — | CN | claimed |
| WO-2024223742-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B PHARMACEUTICALS GMBH (DE) | 2024-10-31 | — | — | WO | claimed |
| CN-118632858-A | Gastric inhibitory peptide receptor ligands | 3B制药有限公司 | 2024-09-10 | — | — | CN | claimed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | claimed |
| CN-118388590-A | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide LFAGA, RDWPEGR, DWPEGR and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-07-26 | — | — | CN | claimed |
| CN-117567562-A | Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 中国水产科学研究院黄海水产研究所 | 2024-02-20 | — | — | CN | claimed |
| CN-116298308-A | Metabolite markers associated with TSC-RAML differential diagnosis and prognosis prediction, and related products and uses | 中国医学科学院北京协和医院 | 2023-06-23 | — | — | CN | claimed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | claimed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | claimed |
| CN-115746102-A | Method for preparing Bulevirtide by combining solid phase with liquid phase | 深圳市健翔生物制药有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115397836-A | Novel antibacterial peptide and application thereof | 安尼根有限公司 | 2022-11-25 | — | — | CN | claimed |
| US-20220167645-A1 | METHODS OF IMPROVING FISH FEED CONVERSION RATE AND SURVIVAL | AQUINOVO LTD. (IL) | 2022-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | ACE 3951/4885ECE1 715/4885KDM4E 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.